Moreover, HER2 and CD24 are both expressed in normal tissues and other cancers, including ovarian and gastric cancers, which could limit the clinical specificity of HER2+ and CD24+ EVs as biomarkers of breast cancer [27, 60]. This evidence concerns the gene CD24 and cancer.